12 completed, 3 active not recruiting, 2 recruiting, 2 unknown. 21 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 21 | Completed 12, Active not recruiting 3, Recruiting 2, Unknown 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Fluid Therapy: new trials by email Literature Review of Fluid Therapy trials Research Report on Fluid Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SGB for Prevention of Postop A-Fib After Cardiac SurgeryTrial Stellate Ganglion Block Injection with 10 mL 0.5% Bupivacaine, Stellate Ganglion Block Injection with 10 mL Normal Saline - Atrial Fibrillation, Postoperative Atrial Fibrillation | Phase 3 | Not yet recruiting | The Cleveland Clinic | 60 | 2026-10-15 | 2026-10-27 |
| Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies IgPro20 - Secondary Immune Deficiency | Phase 3 | Recruiting | CSL Behring | 63 | 2026-09-15 | 2026-10-14 |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy - Multiple Myeloma | Phase 3 | Completed | National Cancer Institute (NCI) | 1 | 2022-02-16 | 2025-05-23 |
| Australasian Resuscitation In Sepsis Evaluation: FLUid or Vasopressors In Emergency Department Sepsis Vasopressor, Fluids - Shock, Septic | Phase 3 | Active not recruiting | Australian and New Zealand Intensive Care Research Centre | 1000 | 2021-10-26 | 2026-11-09 |
| A Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A PXT3003, PXT3003 placebo - Charcot-Marie-Tooth Type 1A | Phase 3 | Completed | Tasly GeneNet Pharmaceuticals Co., Ltd | 176 | 2021-09-28 | 2025-01-09 |
| Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Vigabatrin, Rapamycin, Placebo - Tuberous Sclerosis Complex | Phase 2 / Phase 3 | Recruiting | Katarzyna Kotulska | 60 | 2021-05-07 | 2026-10-22 |
| Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency GC5107 - Primary Immune Deficiency | Phase 3 | Active not recruiting | GC Biopharma Corp | 24 | 2020-12-21 | 2025-07-25 |
| Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate - Mantle Cell Lymphoma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 689 | 2017-11-27 | 2026-09-14 |
| Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID IgG Next Generation (BT595) - Primary Immunodeficiency Disease | Phase 3 | Completed | Biotest | 81 | 2016-10-04 | 2023-07-20 |
| Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency GC5107 - Immunologic Deficiency Syndromes | Phase 3 | Completed | Green Cross Corporation | 49 | 2016-10-01 | 2022-12-09 |
| Resuscitation With Albumin 5% in Dengue Haemorrhagic Fever Albumins, Fluid - Dengue Hemorrhagic | Phase 3 | Unknown | Universitas Indonesia | 84 | 2016-10-01 | 2019-09-03 |
| A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis Oral Rehydration Therapy, Domperidone, Placebo - Gastroenteritis | Phase 3 | Terminated | Janssen-Cilag International NV | 10 | 2015-12-07 | 2019-03-20 |
| Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema C1 esterase inhibitor [human] liquid, Placebo - Hereditary Angioedema (HAE) | Phase 3 | Completed | Shire | 75 | 2015-11-01 | 2021-06-08 |
| Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV 1-dose cIPV + 2-doses bOPV (Candy), 1-dose sIPV + 2-doses bOPV (Candy), 2-doses cIPV + 1-dose bOPV (Candy) - Poliomyelitis | Phase 3 | Completed | Institute of Medical Biology, Chinese Academy of Medical Sciences | 1200 | 2015-09-15 | 2023-10-11 |
| Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock Melatonin - Severe Sepsis, Septic Shock | Phase 3 | Unknown | Aragon Institute of Health Sciences | 110 | 2013-05-01 | 2013-05-21 |
| Emollients in the Management of Atopic Dermatitis glycerol, paraffin (liquid and white soft), Atopiclair®, Locatop@ - Atopic Dermatitis | Phase 3 | Completed | Pierre Fabre Medicament | 347 | 2013-02-01 | 2014-02-19 |
| Study to Assess Longer-term Opioid Medication Effectiveness (SALOME) Hydromorphone, Injectable, Diacetylmorphine, injectable, Hydromorphone, liquid oral - Opioid Dependence, Heroin Dependence | Phase 3 | Completed | University of British Columbia | 202 | 2011-12-01 | 2016-06-07 |
| Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ - Immunologic Deficiency Syndrome | Phase 3 | Completed | Green Cross Corporation | 45 | 2011-09-01 | 2014-01-10 |
| ENterogermina® (Bacillus Clausii) In the manaGeMent of diarrheA in Children Bacillus Clausii, Oral rehydration therapy - Gastroenteritis | Phase 3 | Completed | Sanofi | 264 | 2007-03-01 | 2009-01-21 |
| Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, (CAIV-T) in Healthy Children CAIV-T, Liquid - Healthy | Phase 3 | Completed | MedImmune LLC | 1920 | 2002-02-01 | 2006-10-03 |
Showing 20 of 21. Sign in to see all of them.
Primary Immunodeficiency Diseases (3) · Gastroenteritis (2) · Immunologic Deficiency Syndromes (2) · Multiple Myeloma (2) · Shock, Septic (2) · Agammaglobulinemia (1) · Angioedemas, Hereditary (1) · Atrial Fibrillation (1) · Burkitt Lymphoma (1) · Dengue (1) · Dermatitis (1) · Dermatitis, Atopic (1) · Eczema (1) · Epilepsy (1) · Hematologic Neoplasms (1)
Green Cross Corporation (2) · MedImmune LLC (2) · Aragon Institute of Health Sciences (1) · Australian and New Zealand Intensive Care Research Centre (1) · Biotest (1) · CSL Behring (1) · ECOG-ACRIN Cancer Research Group (1) · GC Biopharma Corp (1) · Institute of Medical Biology, Chinese Academy of Medical Sciences (1) · Janssen-Cilag International NV (1) · Katarzyna Kotulska (1) · National Cancer Institute (NCI) (1) · Pierre Fabre Medicament (1) · Sanofi (1) · Shire (1)
United States (8) · Canada (5) · Spain (5) · China (3) · Germany (3) · Poland (3) · Belgium (2) · France (2) · Hungary (2) · Romania (2) · Russia (2) · United Kingdom (2) · Australia (1) · Austria (1) · Bosnia and Herzegovina (1)
Chaim Roifman, MD (1) · Eugenia Oveido-Joekes, Ph.D. (1) · Gergely Krivan, MD (1) · Katarzyna Kotulska-Jozwiak (1) · Marta Kelava, MD (1) · Michael R Krausz, M.D. (1) · Robert Walker, MD (1) · Rosario Z. Capeding, Dr. (1) · Rui Liu (1) · Sandra Peake, MBBS (1) · Shah Pratik (1) · Shaji K Kumar (1)
PMID 25619263, PMID 27049826, PMID 28526048, PMID 30682573, PMID 31181017, PMID 33288485, PMID 34305948, PMID 35044877, PMID 35944615, PMID 36326435, PMID 36383294, PMID 36485104, PMID 39350232, PMID 40685240, PMID 42274006
2015 (2), U10CA180820 (2)